Product Description
HB-101 is a bivalent recombinant vaccine against human CMV infection.
Mechanisms of Action: Vaccine
Novel Mechanism: No
Modality: Vaccine
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Hookipa Biotech
Company Location: NEW YORK NY 10016
Company CEO: Joern Aldag
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Denmark, France, Germany, Norway, United Kingdom, United States
Active Clinical Trial Count: 2
Highest Development Phases
Phase 2: Cytomegalovirus Infections|Kidney Transplant
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
H-100-002 | P2 |
Completed |
Cytomegalovirus Infections|Kidney Transplant |
2022-06-22 |
|
2017-005047-32 | P2 |
Completed |
Kidney Transplant |
2022-06-22 |